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Sirolimus in Kidney Transplantation:
A Pilot Study in Chinese Patients
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Sing-Leung Lui, Kar-Neng Lai, Tak-Mao Chan
We conducted a pilot open-label study on the use of sirolimus in 10 Chinese patients undergoing kidney
transplantation who received triple prophylactic immunosuppression comprising prednisolone, cyclosporine
and sirolimus. Sirolimus was given as a 6 mg loading dose followed by 2 mg/day maintenance. All patients
achieved target sirolimus trough serum concentrations exceeding 5 ng/mL. Median duration of follow-up was
22 months after transplantation. One patient developed Type Ia acute cellular rejection at 6 months, which
responded to pulse steroid therapy. Graft survival was 100% at 12 months and serum creatinine was 131 (
36 +mol/L at 1 year. Low-density lipoprotein cholesterol and triglyceride levels were significantly increased
after 2 months. Eight patients received atorvastatin, which was subsequently discontinued successfully in three
patients. Infection was noted in two patients; one died of pneumocystis pneumonia 10 months after transplantation
and the other had septicemia from urinary tract infection complicating graft vesicoureteric reflux. Two patients
developed lymphocele in the early postoperative period, which resolved spontaneously in one patient and was
treated successfully with ethanol sclerotherapy in the other. No patients developed thrombocytopenia or
arthralgia. We conclude that sirolimus, when used together with prednisolone and cyclosporine, is well tolerated
and effective in Chinese renal allograft recipients, and that hyperlipidemia early after transplantation is the
most common adverse effect. [Hong Kong J Nephrol 2004;6(1):38–42]
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INTRODUCTION
The advent of new immunosuppressant agents in recent
years has markedly reduced the incidence of acute renal
allograft rejection and improved short-term graft
survival. While calcineurin inhibitors remain pivotal
in postoperative immunosuppressive treatment, their
side effects (such as nephrotoxicity and hypertension)
present significant concerns, especially with regard
to long-term renal allograft survival. As a result, there
is continuing effort to develop immunosuppressive
treatment regimens that incorporate alternative agents
and minimize the use of calcineurin inhibitors.
Sirolimus is more effective than azathioprine or
placebo in reducing acute renal allograft rejection when
used together with corticosteroid and cyclosporine
[1,2]. Its mechanism of action is distinct from that of
calcineurin inhibitors. The complex formed from
sirolimus and FK binding protein 12 binds the mamma-
lian target of rapamycin [3,4] and inhibits both DNA
and protein synthesis, resulting in an arrest of the cell
cycle from late G1 to the S phase [5]. Through these
mechanisms, sirolimus inhibits both T cell proliferation
[6] and the proliferation, differentiation and immuno-
globulin synthesis of B cells [7,8]. In vitro studies
have shown that when sirolimus and cyclosporine
are used together, lower doses of both can achieve
the same degree of cell-mediated lympholysis com-
pared to when each drug is used alone, suggesting
that sirolimus acts synergistically with cyclosporine
in the inhibition of pro-inflammatory cytokine
transcription cytokine-mediated signal transduction.
There is a similar synergistic effect in their inhibition
of proliferation of an interleukin-2 dependent cell-line
[9]. Therefore, it is envisaged that lower doses of cyclo-
sporine may be sufficient in renal allograft recip-
ients who are treated concomitantly with sirolimus,
minimizing the potential adverse effects of cyclo-
sporine.
While sirolimus is assuming increasing impor-
tance in the treatment of renal allograft recipients [10],
the available data are predominantly from patients
of Caucasian or African origin. There are few data
on the use of sirolimus in Asian patients. Further-
more, determination of sirolimus trough levels is of
clinical relevance, since immunosuppressive effica-
cy is related to drug exposure, and there is consider-
able interpersonal variation [11,12]. Again, there is
no information on whether the conventional doses
of sirolimus in Caucasian subjects can achieve
the recommended blood levels in Asian patients.
We report the results of a pilot study using com-
bined prophylactic immunosuppressive treatment
with sirolimus, cyclosporine and prednisolone in
Chinese patients who had undergone kidney trans-
plantation.
PATIENTS AND METHODS
This was an open-label, single-arm, phase 4 clinical
study approved by the Institutional Review Board of
the University of Hong Kong/Hospital Authority Hong
Kong West Cluster. Consecutive patients undergoing
kidney transplantation at our renal unit were enrolled
after they had given written informed consent. Patients
were included if they were over 18 years of age and
had received a primary renal transplant of cadaveric or
living-donor origin. Patients with no human leukocyte
antigen mismatches, who were hepatitis B or C carriers,
those undergoing repeated kidney transplantation or
transplantation involving multiple organs, patients with
high (> 50%) panel reactivity, patients given biologic
induction therapy, and those receiving immuno-
suppressive agents other than sirolimus, cyclosporine
or prednisolone were excluded.
All patients received triple prophylactic immu-
nosuppressive therapy. Intravenous methylpredniso-
lone (3 mg/kg/day) was given for the first 3 days, fol-
lowed by 30 mg/day orally. The dose was tapered to
10 mg/day after around 4 months. Cyclosporine (Neo-
ral®; Novartis Pharmaceuticals Corporation, Basel,
Switzerland) 8 mg/kg/day was started preoperatively;
the target cyclosporine trough blood levels were 270–
300 +g/L for the first 3 months, 200–250 +g/L up to 6
months, and 180–220 +g/L up to 1 year. Sirolimus
(Rapamune®; Wyeth (HK) Ltd, Hong Kong SAR,
China) was administered within 48 hours after
transplantation, with a starting dose of 6 mg orally
followed by 2 mg/day. The intake of sirolimus was
separated from that of cyclosporine by 4 hours. Trough
sirolimus levels were measured every 3 months from
baseline using high performance liquid chromatogra-
phy (HPLC), and the sirolimus maintenance dose was
increased if the level was below 5 ng/mL. All patients
received cotrimoxazole 480 mg/day for 6 months as
prophylaxis against Pneumocystis carinii infection.
Patients were seen once or twice a week for 4 weeks,
then fortnightly for 3 months, then every 3 weeks up to
9 months, and finally, every 3 to 4 weeks until 12
months after transplantation. Thereafter, they were seen
at 4- to 8-week intervals. At each follow-up visit, clin-
ical parameters, including blood pressure, were re-
corded, and routine investigations including renal and
liver biochemistry, blood glucose level, complete blood
picture, urinalysis, and cyclosporine trough level were
carried out. Total cholesterol, triglyceride, high-density
lipoprotein (HDL)-cholesterol, and low-density lipo-
protein (LDL)-cholesterol were measured at baseline,
before discharge after the transplant operation, month-
ly up to 6 months, then every 3 months. Patients with
hyperlipidemia were treated according to the Nation-
al Cholesterol Education Program Guidelines [13].
Advice on diet and physical activity constituted first-
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line management. Atorvastatin therapy, beginning at
10 mg daily, was administered to patients with per-
sistent elevation of LDL-cholesterol. Gemfibrozil was
permitted for patients with isolated hypertriglyceri-
demia (> 1.7 mmol/L). In patients with persistent se-
vere elevation of LDL-cholesterol (> 4.1 mmol/L)
or triglyceride (> 3.0 mmol/L) despite appropriate
pharmacologic and non-pharmacologic therapy,
discontinuation of sirolimus was considered. Other
investigations, including CMVpp65 antigenemia, were
performed when clinically indicated. Acute rejection
was suspected and renal biopsy was performed when
the serum creatinine level increased by more than 15%
above baseline in the absence of identifiable causes such
as cyclosporine nephrotoxicity.
The incidence of acute rejection within the first
12 months was the primary end-point. Secondary end-
points included the severity of acute rejection, graded
according to the Banff 97 classification [14], graft and
patient survival, serum creatinine at 6 and 12 months,
and lipid profile after transplantation. We also examined
the trough serum levels of sirolimus.
Statistics
Results are expressed as median and range unless stat-
ed otherwise. Serial data were compared using the
Wilcoxon signed rank test.
RESULTS
Ten patients were studied for a median duration of
22.0 months (range, 12.0–28.0 months) after kidney
transplantation (Table 1). None of the patients had
diabetes mellitus but one patient was receiving statin
treatment before kidney transplantation. One episode
of acute rejection was noted during follow-up. This
Type Ia rejection occurred at 6 months and respond-
ed to intravenous pulse methylprednisolone therapy at
500 mg given for 3 days. Graft survival was 100% at
12 months. One patient died at 10 months from respi-
ratory distress syndrome secondary to pneumocystis
pneumonia.
With a standard maintenance sirolimus dose of
2 mg/day, the mean dose was 1.26 ( 0.13 mg/m2 (range,
1.10–1.47 mg/m2). All patients had sirolimus trough
levels within the range of 5–15 ng/mL and none re-
quired dose adjustment. Mean sirolimus trough levels
at 3, 6, and 12 months were 7.8 ( 1.4, 9.3 ( 1.4, and
11.7 ( 3.7 ng/mL, respectively (p < 0.05, comparing
12-month with 3- or 6-month levels). Corresponding
mean cyclosporine trough levels were 260 ( 64, 175 (
42, and 169 ( 24 +g/L, respectively (p < 0.05,
comparing 12-month with 3- or 6-month levels). There
was no clinically evident acute cyclosporine
nephrotoxicity. Mean serum creatinine levels were
stable at 1, 3, 6, and 12 months (138 ( 45, 136 ( 43,
147 ( 53, and 131 ( 36 +mol/L, respectively; p = 0.30;
Figure).
Hyperlipidemia was the most common adverse
effect. Total cholesterol, LDL-cholesterol, and
triglyceride levels were significantly increased after 2
months compared to baseline (Table 2), with six and
nine patients having triglyceride and LDL-cholesterol
levels exceeding 1.7 mmol/L and 3.4 mmol/L (the upper
limits for our laboratory), respectively. Atorvastatin
treatment was given to eight patients at a median
interval of 2.4 months (range, 0.8–4.5 months) after
transplantation. The median level of LDL-cholesterol in
these patients was 5.8 mmol/L (range, 4.5–7.5 mmol/L)
when treatment was started. No patients had isolated
hypertriglyceridemia. Subsequent reduction of ator-
vastatin dose was possible within the first year in three
patients who had significant improvement of hyper-
lipidemia. Twelve months after transplantation, six pa-
tients were still receiving atorvastatin treatment; the
mean levels of triglyceride and LDL-cholesterol were
3.18 ( 0.73 mmol/L and 2.03 ( 1.06 mmol/L, respec-
tively, in the atorvastatin-treated group, compared with
3.05 mmol/L and 1.9 mmol/L in the three patients not
receiving atorvastatin.
Infection occurred in two patients during follow-
up. The patient who had an episode of acute rejec-
Table 1. Characteristics of 10 Chinese renal allograft recipients
treated with prednisolone, cyclosporine, and sirolimus.
Gender 7 male, 3 female
Age, yr 34 (range, 28–52)
Body weight, kg 54.7 (range, 45.4–71.0)
Body surface area, m2 1.59 (range, 1.36–1.82)
Mode of dialysis 7 peritoneal dialysis, 3 hemodialysis
Duration of dialysis, mo 31 (range, 12–198)
Type of organ donor 5 cadaveric, 5 living-related
Figure. Serial serum creatinine concentration during the first 12
months after kidney transplantation in 10 Chinese patients given
triple immunosuppression with sirolimus, cyclosporine and
prednisolone.
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tion necessitating pulse steroid therapy developed
pneumocystis pneumonia at 10 months, despite
cotrimoxazole prophylaxis during the first 6 months,
and died from respiratory distress syndrome. This was
the only mortality. Another patient with severe allograft
vesicoureteric reflux developed urinary tract infection
with Escherichia coli septicemia at month 13 that
responded to antibiotic therapy. Two patients developed
lymphocele. One patient had persistent lymph drainage
after transplantation together with a non-obstructive
lymphocele, which responded to ethanol sclerotherapy.
The lymphocele in the other patient resolved after
aspiration. No patient had thrombocytopenia (platelet
count < 150 = 109/L), marrow suppression, cyto-
megalovirus disease, arthralgia, or malignancy.
DISCUSSION
These results demonstrate that a sirolimus loading dose
of 6 mg followed by 2 mg/day maintenance is well
tolerated in Chinese renal allograft recipients, and that
triple prophylactic immunosuppression with sirolimus,
cyclosporine, and corticosteroid is associated with a
low incidence of acute rejection and satisfactory short-
term graft survival. The single episode of acute cellular
rejection occurred in a patient with a prolonged cold
ischemia time of 15 hours and delayed graft function,
the latter necessitating hemodialysis support for 1 week.
It has been suggested that Afro-Americans may
require a higher serum concentration of sirolimus (and
thus a maintenance dose * 5 mg/day) to prevent acute
rejection [15]. Chinese subjects in general have a
smaller body frame, thereby resulting in a higher dos-
age normalized according to body surface area com-
pared to Caucasians. The small sample of this pilot
study does not permit definitive comparison of the
dose of 1.26 mg/m2 among our patients with other re-
ports. Sirolimus serum concentration demonstrates
significant individual variation and cannot be predicted
based on anthropometric calculations of body size.
Ethnic variations in drug metabolism, confounded by
dietary interference, may also affect the serum con-
centration and, thus, the optimal dose. Nevertheless,
the results of our pilot study suggest that a 6 mg loading
followed by 2 mg/day maintenance is adequate for
Chinese renal allograft recipients. This dose regimen
achieved trough serum levels exceeding the target of
5 ng/mL in all 10 patients, with an average of 10.0 ng/mL.
Further studies are necessary to examine whether the
trend of increasing serial sirolimus concentrations over
time is sustained and whether this increase has clinical
implications.
The serum creatinine concentration in our patients
remained stable throughout the study. Nevertheless, the
potential for sirolimus to enhance the nephrotoxic effect
of cyclosporine is a significant concern [16,17], since
patients on sirolimus, cyclosporine, and prednisolone
show higher serum creatinine concentrations and higher
systolic and diastolic blood pressure readings compared
with patients from whom cyclosporine is withdrawn
after the initial 3 months [18]. In this context, there is
an emerging trend towards calcineurin inhibitor
minimization in long-term patients receiving sirolimus
or mycophenolate mofetil concomitantly, in order to
reduce the risk of chronic nephrotoxicity [19–22].
Similar to data from Caucasian subjects [23,24],
hyperlipidemia was the most common side effect of
sirolimus therapy, necessitating lipid-lowering therapy
in eight of the 10 patients within the first year after
transplantation. Previous studies have demonstrated that
sirolimus increases high-density lipoproteins, but more
so low-density lipoproteins and triglycerides, mediated
through delayed clearance of lipoprotein remnants
[25]. The predominant abnormality observed in the
present study was an increase in LDL-cholesterol,
which persisted after a trial of dietary control. The hyper-
lipidemia responded satisfactorily to treatment with
atorvastatin, and as the dose of prednisolone was re-
duced, atorvastatin could be successfully discontinued
in some patients. At 12 months after transplantation,
six of the 10 patients still required atorvastatin. For
comparison, 20.3% of renal allograft recipients treated
with prednisolone and cyclosporine in the absence of
Table 2. Lipid profile in 10 renal allograft recipients given triple immunosuppression with sirolimus, cyclosporine and prednisolone.
Before treatment 2nd month 4th month 6th month 9th month 12th month
TC, mmol/L 5.05 (3.60–7.40) 7.20 (5.30–10.20)* 6.45 (4.30–7.90) 5.35 (3.80–6.90) 6.20 (4.40–6.70) 5.50 (4.50–6.60)
LDL-C, mmol/L 3.00 (2.00–5.20) 4.45 (3.10–6.90)* 3.70 (2.20–6.10) 2.75 (2.10–4.40) 3.20 (2.40–4.20) 2.95 (2.50–4.50)
Triglyceride, mmol/L 1.15 (0.90–3.10) 2.45 (1.00–5.10)* 1.60 (1.20–4.30) 2.05 (1.30–3.00)* 2.20 (1.00–2.90) 1.90 (0.90–3.90)
HDL-C, mmol/L 1.19 (0.74–1.81) 1.47 (1.13–3.15)* 1.39 (0.96–2.73) 1.25 (1.02–2.45) 1.34 (0.78–2.40) 1.19 (0.89–2.10)
No. of patients on statin 1 4 6 8 8 6
Data presented as median (range). *p < 0.05 compared to baseline. TC = total cholesterol; LDL-C = low-density lipoprotein cholesterol;
HDL-C = high-density lipoprotein cholesterol.
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sirolimus develop hypercholesterolemia and 6.8%
require statin therapy within the first post-transplant
year [26].
An increased incidence of surgical wound compli-
cations or lymphocele is a recognized risk with siro-
limus, attributed to interference with wound healing.
While none of our patients had problems with wound
healing, two developed lymphoceles. The latter there-
fore warrants vigilant surveillance during follow-up.
We conclude from this pilot study that triple thera-
py with sirolimus, cyclosporine, and prednisolone as
prophylactic immunosuppression is, in general, well
tolerated and effective in Chinese subjects. Sirolimus
given as a 6 mg loading dose followed by 2 mg/day
maintenance can achieve target blood levels exceeding
5 ng/mL in the presence of a calcineurin inhibitor. It is
pertinent to monitor patients for the development of
hyperlipidemia and lymphocele, so that treatment can
be instituted promptly.
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